NCT04053283: First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector

NCT04053283
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic brain or leptomeningeal metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT04053283

Comments are closed.

Up ↑